How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?
A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and next-generation incretin therapies deliver substantial weight loss while reducing cardiovascular and kidney risks. Emerging…